BIO 2009: Ontario Premier’s Breakfast
The speeches (s-peach-es?) just finished this morning at the Ontario Premier’s breakfast. Minister of Research and Innovation John Wilkinson announced that Ontario has recently completed 2 new BIP...
View ArticleIVB’s Great Take on the GSK-Pfizer HIV Joint Venture
The In Vivo Blog has a really interesting post by Roger Longman discussing what they view as the groundbreaking and innovative aspects of GSK and Pfizer’s HIV joint venture, announced just over a month...
View ArticleTrends Update — IP Constituencies: Rumors about GSK-Shantha Biotech
Since we’ve been following innovative activity in India and China as part of our Trends in 2009 series, we had noted a report at the end of March that GlaxoSmithKline and Sanofi-Aventis were each in...
View ArticleNovel Deal Structures Becoming More Common
At the RIC/OCETA talk I participated in last month, one of the trends in deal-making that I mentioned was novel structures. At the time, examples included option deals and new ways to split rights and...
View ArticleNo Company is an Island: More Pharma and Biotech Collaboration
Two deals this week showcase collaborative efforts between major pharma players: Gilead Sciences Inc. entered a partnership with Tibotec Pharmaceuticals, a unit of J&J, to develop a single...
View ArticlePlanned UK Bioscience Park Features “Open Innovation,” is Brought to You By...
A new biotech “hub” (aka campus, park, centre, cluster…) is being planned at GSK’s Stevenage Campus in the UK. Whatever you call it, the organizers are pitching two novel features: An “Open...
View ArticleDreaming of REMS: A Second Reason Why FDAAA Risk Evaluation and Mitigation...
Over at The In Vivo Blog, Michael McCaughan has another thought-provoking piece on REMS — the FDA’s Risk Evaluation and Mitigation Strategies that impose tight controls on the distribution channels for...
View ArticlePersonalized Medicine Conference Highlights a Busy Month
Last week, Harvard Medical School held a conference entitled “Personalized Medicine: The Time is Now.” Is the time now? Looking around, it seems like personalized medicine has had a pretty good...
View ArticleMonday Biotech Deal Review: December 21, 2009
This week’s deal review shows no signs of a holiday showdown. In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma...
View ArticlePatent Cliff Will Not Save Biotech: Abbott Buys Indian Generics Company...
I often hear how the upcoming loss of patent protection for current blockbusters creates an insatiable demand at pharma companies for new pipeline products from biotechs. Here’s an example from 2007....
View Article
More Pages to Explore .....